{"id":"https://openalex.org/W4300580431","doi":null,"title":"Drugs for Alzheimer's disease: best avoided. No therapeutic advantage.","display_name":"Drugs for Alzheimer's disease: best avoided. No therapeutic advantage.","publication_year":2012,"publication_date":"2012-06-01","ids":{"openalex":"https://openalex.org/W4300580431","pmid":"https://pubmed.ncbi.nlm.nih.gov/22822592"},"language":"en","primary_location":{"id":"pmid:22822592","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/22822592","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Prescrire international","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.2155,"has_fulltext":false,"cited_by_count":12,"citation_normalized_percentile":{"value":0.55799349,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"21","issue":"128","first_page":"150","last_page":"150"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12023","display_name":"Cholinesterase and Neurodegenerative Diseases","score":0.5981000065803528,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12023","display_name":"Cholinesterase and Neurodegenerative Diseases","score":0.5981000065803528,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10086","display_name":"Alzheimer's disease research and treatments","score":0.2222999930381775,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10009","display_name":"Dementia and Cognitive Impairment Research","score":0.09220000356435776,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/alzheimer-s-disease","display_name":"Alzheimer's disease","score":0.9990000128746033},{"id":"https://openalex.org/keywords/cholinesterase-inhibitors","display_name":"cholinesterase inhibitors","score":0.9900000095367432},{"id":"https://openalex.org/keywords/memantine","display_name":"memantine","score":1.0},{"id":"https://openalex.org/keywords/drug-reimbursement","display_name":"drug reimbursement","score":0.7009999752044678},{"id":"https://openalex.org/keywords/pharmacoeconomics","display_name":"pharmacoeconomics","score":0.777999997138977}],"concepts":[{"id":"https://openalex.org/C2779484449","wikidata":"https://www.wikidata.org/wiki/Q412189","display_name":"Memantine","level":4,"score":0.8082611560821533},{"id":"https://openalex.org/C2779703844","wikidata":"https://www.wikidata.org/wiki/Q760125","display_name":"Reimbursement","level":3,"score":0.7323499917984009},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.673071026802063},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5682723522186279},{"id":"https://openalex.org/C2776332859","wikidata":"https://www.wikidata.org/wiki/Q411887","display_name":"Rivastigmine","level":5,"score":0.5338389277458191},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.5047770738601685},{"id":"https://openalex.org/C31896038","wikidata":"https://www.wikidata.org/wiki/Q415635","display_name":"Cholinesterase","level":2,"score":0.45051872730255127},{"id":"https://openalex.org/C502032728","wikidata":"https://www.wikidata.org/wiki/Q11081","display_name":"Alzheimer's disease","level":3,"score":0.44530174136161804},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3254617154598236},{"id":"https://openalex.org/C2780904820","wikidata":"https://www.wikidata.org/wiki/Q415081","display_name":"Donepezil","level":4,"score":0.29300251603126526},{"id":"https://openalex.org/C2779483572","wikidata":"https://www.wikidata.org/wiki/Q83030","display_name":"Dementia","level":3,"score":0.28942564129829407},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.1716083288192749},{"id":"https://openalex.org/C160735492","wikidata":"https://www.wikidata.org/wiki/Q31207","display_name":"Health care","level":2,"score":0.0870802104473114},{"id":"https://openalex.org/C17744445","wikidata":"https://www.wikidata.org/wiki/Q36442","display_name":"Political science","level":0,"score":0.06588160991668701},{"id":"https://openalex.org/C199539241","wikidata":"https://www.wikidata.org/wiki/Q7748","display_name":"Law","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000544","descriptor_name":"Alzheimer Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D002800","descriptor_name":"Cholinesterase Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008559","descriptor_name":"Memantine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false}],"locations_count":1,"locations":[{"id":"pmid:22822592","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/22822592","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Prescrire international","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9537000060081482,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2893692250","https://openalex.org/W2056279628","https://openalex.org/W2417018496","https://openalex.org/W3140878214","https://openalex.org/W2524224467","https://openalex.org/W2072543577","https://openalex.org/W2883176237","https://openalex.org/W2140116196","https://openalex.org/W2513728792","https://openalex.org/W2182468513"],"abstract_inverted_index":{"The":[0],"French":[1],"Pharmacoeconomic":[2],"Committee":[3],"that":[4],"assesses":[5],"the":[6,22],"medical":[7,23],"benefit":[8,24],"of":[9,21],"new":[10],"drugs":[11],"and":[12,33],"provides":[13],"recommendations":[14],"about":[15],"reimbursement":[16],"has":[17],"downgraded":[18],"its":[19],"rating":[20],"(SMR,":[25],"service":[26],"mddical":[27],"rendu)":[28],"provided":[29],"by":[30],"cholinesterase":[31],"inhibitors":[32],"memantine":[34],"in":[35],"Alzheimer's":[36],"disease":[37],"from":[38],"\"major\"":[39],"to":[40],"\"low\".":[41]},"counts_by_year":[{"year":2021,"cited_by_count":2},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":5},{"year":2017,"cited_by_count":2},{"year":2015,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2022-10-03T00:00:00"}